|
|
INI-4001 |
|
Vaxjo ID |
167 |
|
Vaccine Adjuvant Name |
INI-4001 |
|
Adjuvant VO ID |
VO_0005288
|
|
Description |
INI-4001 is a TLR7/8 agonist that induces a biased Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (U. Montana and Inimmune) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
synthetic TLR7/8 agonist |
|
Preparation |
liposome, aqueous solution, can have adsorption to alum |
|
Function |
innate immune activation, induces mucosal immunity |
| References |
(Ryter, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=28]
Miller et al., 2023: Miller SM, Crouse B, Hicks L, Amin H, Cole S, Bazin HG, Burkhart DJ, Pravetoni M, Evans JT. A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. NPJ vaccines. 2023; 8(1); 97. [PubMed: 37429853].
|
|
